# Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC

> **NCT04470024** · PHASE1 · RECRUITING · sponsor: **Providence Health & Services** · enrollment: 56 (estimated)

## Conditions studied

- Cancer of the Head and Neck

## Interventions

- **DRUG:** INCAGN01876
- **DRUG:** INCMGA00012
- **BIOLOGICAL:** DPV-001

## Key facts

- **NCT ID:** NCT04470024
- **Lead sponsor:** Providence Health & Services
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-08-05
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04470024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04470024, "Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04470024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*